Ovid Therapeutics to Participate in Upcoming Investor Conferences
Ovid Therapeutics plans September 2026 webcasted presentations at Cantor and H.C. Wainwright investor conferences, with replays available online for 30 days.
Rhea-AI Summary
Ovid Therapeutics (OVID) will participate in two upcoming investor conferences in September 2026. Management will present at the Cantor Global Healthcare Conference on September 9 at 2:10 pm ET and at the H.C. Wainwright 28th Annual Global Investment Conference on September 14 at 11:30 am ET. Webcasts and 30-day replays will be available via the Events & Presentations section of the company’s investor website.
Positive
- None.
Negative
- None.
Market Reaction – OVID
Following this news, OVID has gained 2.40%, reflecting a moderate positive market reaction. The stock is currently trading at $2.77.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in two upcoming investor conferences:
- Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ET
- H.C. Wainwright 28th Annual Global Investment Conference – Monday, September 14 at 11:30 am ET
Webcasts of the presentations can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com. An archived replay of the webcasts will be available on the Company’s website following the live presentation for approximately 30 days.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. The Company discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with significant unmet need. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant FOS and DEEs, including TSC and IS; and OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit www.ovidrx.com
Contact
Investor Relations & Media
Investors@ovidrx.com
202.361.0445
